What is JBIO's earnings yield?

JBIO (JBIO) reported earnings yield of -18.7% in Q1 2026.

What does earnings yield mean?

Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.

JBIO JBIO Earnings yield

Earnings yield at other companies

Vertex PharmaceuticalsVRTX

3.8%—

Travere Therapeutics, Inc.TVTX

-4.2%-1.9pp

Vera TherapeuticsVERA

-12.9%+1.8pp

AnaptysBio, Inc.ANAB

-9.9%-2.8pp

Avalo TherapeuticsAVTX

-24.9%-110pp

Cullinan Therapeutics, Inc.CGEM

-25.7%-6.8pp

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

net income/market cap=-18.7%

Based on trailing twelve months.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's earnings yield?: JBIO (JBIO) reported earnings yield of -18.7% in Q1 2026.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.